.Attributes Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after an average follow-up of 11 months, clients with metastatic gastrointestinal tumors that got biomarker-matched therapies based on flowing cyst DNA profiling revealed a better professional benefit than those obtaining unequaled treatment.